View PowerPoint Presentation - Vision Research Coordinating Center

More documents

Recommendations

Info

No Significant Safety DifferenceBetween Randomization Groups Mortality Hospitalizations New Medical Conditions Worsening of Pre-existingConditions SF – 36/any subscale Patient Reported Ocularand Systemic SymptomsJune, 2002
Percent Reporting Changes inIris, Lids or LashesProstaglandin analog > 6 monthsn = 380Observation groupn = 63117%8%P
Page 1 and 2: The Ocular HypertensionTreatment St
Page 3 and 4: Why did we do this study?Don’t we
Page 5 and 6: Ocular Hypertension Treatment Study
Page 7 and 8: Patient found eligible for OHTS•
Page 9 and 10: Baseline Characteristics by Randomi
Page 15 and 16: IOP By RaceMedicationObservationAfr
Page 17 and 18: Progress and Outcome of Study Parti
Page 19 and 20: Proportion POAG1 st Visual Field PO
Page 21 and 22: First POAG Endpoint per Participant
Page 23: Treatment perhaps less protectivein
Page 27 and 28: Borderline Safety DifferencesBetwee
Page 29 and 30: Significant Baseline Predictive Fac
Page 31 and 32: Significant Baseline Predictive Fac
Page 33 and 34: POAG Endpoints by Central Corneal T
Page 35 and 36: 60-year-old WF IOP 24 / 24 C/D rati
Page 37 and 38: 60-year-old WF IOP 28 / 28 C/D rati
Page 39 and 40: 72-year-old BM IOP 25 / 25 C/D rati
Page 41 and 42: Weaknesses1. Convenience sample rat
Page 43 and 44: Possible Misinterpretations of OHTS
Page 45: OHTS Clinical CentersBascom Palmer

View PowerPoint Presentation - Vision Research Coordinating Center

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?